Table 1 Clinical characteristics for COVID-19 infection in patients with hematology and oncology disease
Characteristics | Total (%) n = 306 | Asymptomatic /Mild n = 283 | Moderate/Severe n = 23 | Univariable Analysis P value |
|---|---|---|---|---|
Age, years | 0.668 | |||
< 1 | 12 (3.9) | 11 | 1 | |
1–10 | 145 (47.4) | 133 | 12 | |
≥10 | 149 (48.7) | 139 | 10 | |
Gender | 0.126 | |||
Male | 181 (59.2) | 171 | 10 | |
Female | 125 (40.8) | 112 | 13 | |
Diseases | 0.440 | |||
Malignant hematology* | 193 (63.1) | 175 | 18 | |
Lymphoma | 24 (7.8) | 24 | 0 | |
Solid tumor | 8 (2.6) | 8 | 0 | |
Benign hematologic disorder † | 29 (9.5) | 27 | 2 | |
Post SCT | 52 (17.0) | 49 | 3 | |
Underlying disease course | < 0.0001 | |||
Intensive chemotherapy | 78 (25.5) | 62 | 16 | |
Maintenance chemotherapy | 98 (32.0) | 95 | 3 | |
Stopped chemotherapy | 130 (42.5) | 126 | 4 | |
<1 year from stopping | 28 (9.2) | - | - | |
1–3 years from stopping | 54 (17.6) | - | - | |
≥3 years from stopping | 48 (15.7) | - | - | |
Target B cells immunotherapy# | 0.115 | |||
Yes | 8 (2.6) | 6 | 2 | |
No | 298 (97.4) | 277 | 21 | |
Vaccination$ | 0.805 | |||
Yes (any dose) | 70 (25.8) | 64 | 6 | |
No | 201 (74.2) | 185 | 16 | |
In immune-compromise stage | 0.793 | |||
Vaccinated | 47 (25.8) | 41 | 6 | |
Non-vaccinated | 135 (74.2) | 120 | 15 | |
COVID-19 continuing time, days (range) | 7 (1–35) | 7 (1–23) | 6.5 (4–35) | 0.753 |
Duration of symptom, days (range) | 4.0 (1.0–20) | 3.5 (1.0–20) | 7.0 (2.0–18) | < 0.0001 |